Home > Healthcare > Medical Devices > Medical Supplies > Glucose Biosensors Market

Glucose Biosensors Market Trends

Report ID: GMI5300
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Glucose Biosensors Market Trends

Recent advancements in glucose biosensors will generate lucrative opportunities for industry growth. Non-invasive glucose monitoring devices are now being developed to eliminate the need for frequent finger pricking and provide continuous glucose monitoring. Technologies, including optical sensors, spectroscopy, and transdermal patches, have gained immense traction in this field. Additionally, continuous glucose monitoring systems, which provide real-time glucose data and can alert users about high or low glucose levels, have gained popularity, further contributing to market revenue.

Authors: Mariam Faizullabhoy

Frequently Asked Questions (FAQ) :

In 2022, the glucose biosensors industry was valued at USD 12.9 billion and will grow at more than 13% CAGR from 2023 to 2032, attributed to the rising incidence of diabetes globally.

Self monitoring blood glucose devices industry was valued at over USD 6 billion in 2022, owing to surging awareness about diabetes risks, its complications, management, and control.

North America glucose biosensors market size will reach more than USD 11.7 billion by 2032, owing to rising investment by the government in diabetes care.

Major glucose biosensors industry players include Lifescan, Inc., Nova Biomedical, Taidoc Technology Corporation, Dexcom, Abbott, Trividia Health, Universal Biosensors, Med Trust, Roche AG., and i-SENS, Inc., among others.